AI Engines For more Details: Perplexity Kagi Labs You
Eczema (Atopic Dermatitis): Prednicarbate is effective in reducing inflammation, itching, and redness associated with eczema. It helps alleviate symptoms and improve the appearance of affected skin areas.
Psoriasis: Prednicarbate can be used to manage mild to moderate psoriasis by reducing inflammation and scaling of the skin. It helps relieve itching and discomfort associated with psoriatic plaques.
Contact Dermatitis: Prednicarbate is used to treat allergic contact dermatitis and irritant contact dermatitis caused by exposure to allergens or irritants. It helps reduce inflammation and soothe the affected skin.
Seborrheic Dermatitis: Prednicarbate may be prescribed to alleviate symptoms of seborrheic dermatitis, including redness, scaling, and itching in areas such as the scalp, face, and chest.
Pruritus (Itching): Prednicarbate can provide relief from itching associated with various skin conditions, including eczema, psoriasis, allergic reactions, and insect bites.
Dermatitis:
Inflammatory Skin Conditions: Prednicarbate is used to treat other inflammatory skin conditions such as dermatitis herpetiformis, lichen planus, and discoid lupus erythematosus.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 2 | 2 | |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 1.8 | 0.1 | 17 |
| Allergies | 1.3 | 0.9 | 0.44 |
| Allergy to milk products | 0.4 | 1.3 | -2.25 |
| Alopecia (Hair Loss) | 0.2 | 0.2 | |
| Alzheimer's disease | 2.2 | 2.9 | -0.32 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.1 | 0.1 | 10 |
| Ankylosing spondylitis | 1.8 | 0.8 | 1.25 |
| Anorexia Nervosa | 0.4 | 1.6 | -3 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 1.4 | 0.8 | 0.75 |
| Atherosclerosis | 0.6 | 0.8 | -0.33 |
| Atrial fibrillation | 1.2 | 2.6 | -1.17 |
| Autism | 3.5 | 3.8 | -0.09 |
| Autoimmune Disease | 0.6 | 0.5 | 0.2 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 1.3 | 0.5 | 1.6 |
| Brain Trauma | 0.8 | -0.8 | |
| Breast Cancer | 0.1 | 0.1 | |
| Cancer (General) | 0.3 | 0 | 0 |
| Carcinoma | 1.6 | 1 | 0.6 |
| Celiac Disease | 1 | 1 | 0 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 1.3 | 1.2 | 0.08 |
| Chronic Kidney Disease | 1.8 | 1.1 | 0.64 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.1 | 0.5 | -4 |
| Chronic Urticaria (Hives) | 0.7 | 0.8 | -0.14 |
| Coagulation / Micro clot triggering bacteria | 1.1 | 0.5 | 1.2 |
| Cognitive Function | 0.7 | 0.8 | -0.14 |
| Colorectal Cancer | 2.7 | 1.2 | 1.25 |
| Constipation | 0.9 | 0.5 | 0.8 |
| Coronary artery disease | 1.4 | 1.9 | -0.36 |
| COVID-19 | 2.1 | 3.5 | -0.67 |
| Crohn's Disease | 3.5 | 2.3 | 0.52 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.7 | 0.8 | -0.14 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 0.9 | 0.8 | 0.13 |
| Depression | 3.1 | 2.9 | 0.07 |
| Eczema | 1.1 | 0.2 | 4.5 |
| Endometriosis | 1.4 | 0.9 | 0.56 |
| Epilepsy | 1.2 | 0.7 | 0.71 |
| erectile dysfunction | 0.9 | 0.9 | |
| Fibromyalgia | 1 | 1.4 | -0.4 |
| Functional constipation / chronic idiopathic constipation | 2 | 2.1 | -0.05 |
| gallstone disease (gsd) | 1.8 | 0.5 | 2.6 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | |
| Generalized anxiety disorder | 1.4 | 0.3 | 3.67 |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.7 | 0.8 | -0.14 |
| Gulf War Syndrome | 0.2 | -0.2 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 1 | 0.3 | 2.33 |
| Heart Failure | 1.9 | 1.1 | 0.73 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.6 | 0.6 | |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.4 | |
| hyperglycemia | 0.7 | 0.7 | 0 |
| hypertension (High Blood Pressure | 1.3 | 1.3 | 0 |
| Hypoxia | 1.4 | 1.4 | |
| IgA nephropathy (IgAN) | 0.7 | 2.1 | -2 |
| Inflammatory Bowel Disease | 2.1 | 3.2 | -0.52 |
| Insomnia | 0.3 | 1.1 | -2.67 |
| Intelligence | 0.8 | 0.7 | 0.14 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 2.2 | 1.7 | 0.29 |
| ischemic stroke | 0.8 | 1.7 | -1.13 |
| Liver Cirrhosis | 2.7 | 0.9 | 2 |
| Long COVID | 2.4 | 1.8 | 0.33 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.6 | 0.6 | |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.6 | 0.6 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.5 | 0.5 | 0 |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 2.9 | 2.2 | 0.32 |
| Mood Disorders | 3 | 2.8 | 0.07 |
| Multiple Sclerosis | 1 | 2.9 | -1.9 |
| myasthenia gravis | 0.6 | 0.5 | 0.2 |
| neuropathic pain | 1.4 | -1.4 | |
| Neuropathy (all types) | 1.7 | -1.7 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.5 | 1.7 | 0.47 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 3.5 | 2.3 | 0.52 |
| obsessive-compulsive disorder | 2 | 2 | 0 |
| Osteoarthritis | 1.8 | 0.3 | 5 |
| Osteoporosis | 1.4 | 0.3 | 3.67 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 2.4 | 3.3 | -0.38 |
| Polycystic ovary syndrome | 2.7 | 1.1 | 1.45 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.4 | -0.4 | |
| Primary sclerosing cholangitis | 0.7 | 1.1 | -0.57 |
| Psoriasis | 0.3 | 2.7 | -8 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3 | 1.9 | 0.58 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.4 | 1.3 | 0.08 |
| scoliosis | 0.1 | 0.1 | |
| Sjögren syndrome | 2 | 1.4 | 0.43 |
| Sleep Apnea | 0.8 | -0.8 | |
| Slow gastric motility / Gastroparesis | 0.4 | 0.4 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.4 | |
| Stress / posttraumatic stress disorder | 1.3 | 1.3 | 0 |
| Systemic Lupus Erythematosus | 2.3 | 0.8 | 1.87 |
| Tic Disorder | 0.3 | 0.7 | -1.33 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.1 | 0.8 | 0.38 |
| Type 2 Diabetes | 3.2 | 2 | 0.6 |
| Ulcerative colitis | 1.6 | 2.8 | -0.75 |
| Unhealthy Ageing | 1 | 1.9 | -0.9 |
| Vitiligo | 0.9 | 0.4 | 1.25 |
